Spatial Transcriptomics Reveals Signatures of Histopathological Changes in Muscular Sarcoidosis.

Visium fibrosis granuloma muscular sarcoidosis skeletal muscle spatial transcriptomic

Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
30 Nov 2023
Historique:
received: 09 11 2023
revised: 25 11 2023
accepted: 27 11 2023
medline: 9 12 2023
pubmed: 9 12 2023
entrez: 9 12 2023
Statut: epublish

Résumé

Sarcoidosis is a multisystemic disease characterized by non-caseating granuloma infiltrating various organs. The form with symptomatic muscular involvement is called muscular sarcoidosis. The impact of immune cells composing the granuloma on the skeletal muscle is misunderstood. Here, we investigated the granuloma-skeletal muscle interactions through spatial transcriptomics on two patients affected by muscular sarcoidosis. Five major transcriptomic clusters corresponding to perigranuloma, granuloma, and three successive muscle tissue areas (proximal, intermediate, and distal) around the granuloma were identified. Analyses revealed upregulated pathways in the granuloma corresponding to the activation of T-lymphocytes and monocytes/macrophages cytokines, the upregulation of extracellular matrix signatures, and the induction of the TGF-β signaling in the perigranuloma. A comparison between the proximal and distal muscles to the granuloma revealed an inverse correlation between the distance to the granuloma and the upregulation of cellular response to interferon-γ/α, TNF-α, IL-1,4,6, fibroblast proliferation, epithelial to mesenchymal cell transition, and the downregulation of muscle gene expression. These data shed light on the intercommunications between granulomas and the muscle tissue and provide pathophysiological mechanisms by showing that granuloma immune cells have a direct impact on proximal muscle tissue by promoting its progressive replacement by fibrosis via the expression of pro-inflammatory and profibrosing signatures. These data could possibly explain the evolution towards a state of disability for some patients.

Identifiants

pubmed: 38067175
pii: cells12232747
doi: 10.3390/cells12232747
pmc: PMC10706822
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : CNRS and INSERM
ID : CNRS INSERM
Organisme : AFM Téléthon
ID : MyoNeurALP strategic grant
Organisme : Fondation pour la Recherche Médicale
ID : Equipe FRM
Organisme : Hospices Civils de Lyon
ID : Grant of Hospices Civils de Lyon
Organisme : University Claude Bernard Lyon1
ID : Funding from University Claude Bernard Lyon1

Références

J Clin Invest. 2009 Jun;119(6):1583-94
pubmed: 19451692
Int J Mycobacteriol. 2014 Dec;3(4):225-9
pubmed: 26786620
Cureus. 2020 Oct 5;12(10):e10812
pubmed: 33173621
Am J Respir Crit Care Med. 2001 Jan;163(1):115-21
pubmed: 11208635
Lancet. 2012 Nov 24;380(9856):1859
pubmed: 22922001
J Clin Pathol. 1988 Apr;41(4):410-4
pubmed: 3366926
Neurology. 2020 Mar 3;94(9):e910-e920
pubmed: 31882529
Adv Exp Med Biol. 2015;852:59-69
pubmed: 25753554
Lancet. 1998 Aug 1;352(9125):347-52
pubmed: 9717921
Trends Immunol. 2020 Apr;41(4):286-299
pubmed: 32122794
Am J Pathol. 2001 Oct;159(4):1263-73
pubmed: 11583954
PLoS One. 2015 Nov 23;10(11):e0143413
pubmed: 26599547
Semin Arthritis Rheum. 2017 Oct;47(2):288-294
pubmed: 28392046
Int J Mol Sci. 2019 May 17;20(10):
pubmed: 31108916
Cells. 2021 Mar 31;10(4):
pubmed: 33807303
Hum Mol Genet. 2019 Oct 15;28(20):3431-3442
pubmed: 31411676
Medicine (Baltimore). 2016 Mar;95(10):e3089
pubmed: 26962842
Front Physiol. 2021 Apr 20;12:673404
pubmed: 33959042
Nat Commun. 2022 Nov 21;13(1):7058
pubmed: 36411280
Neurol Neuroimmunol Neuroinflamm. 2018 Mar 16;5(3):e452
pubmed: 29845092
Exp Mol Pathol. 2001 Aug;71(1):13-33
pubmed: 11502094
Trends Immunol. 2020 Jun;41(6):481-492
pubmed: 32362490
Cells. 2023 Mar 30;12(7):
pubmed: 37048117
Arterioscler Thromb Vasc Biol. 2013 Jan;33(1):67-75
pubmed: 23117656
Curr Opin Rheumatol. 2021 Nov 1;33(6):522-528
pubmed: 34402455
Proc Natl Acad Sci U S A. 1992 Dec 1;89(23):11518-22
pubmed: 1454841
Neuromuscul Disord. 2022 Jul;32(7):557-563
pubmed: 35654706
Proc Am Thorac Soc. 2012 Jul;9(3):111-6
pubmed: 22802283
Hypertension. 2015 Oct;66(4):767-75
pubmed: 26238446
Am J Pathol. 2011 Mar;178(3):1279-86
pubmed: 21356378
J Am Soc Nephrol. 2009 Mar;20(3):604-12
pubmed: 19158350
J Neuromuscul Dis. 2018;5(2):109-129
pubmed: 29865091
Nat Med. 2015 Jul;21(7):786-94
pubmed: 26053624
PLoS One. 2014 Mar 20;9(3):e92048
pubmed: 24651840
Autoimmun Rev. 2014 Apr-May;13(4-5):372-4
pubmed: 24424169
Clin Chest Med. 2008 Sep;29(3):365-77, vii
pubmed: 18539232
J Neuroimmunol. 2022 Dec 15;373:577975
pubmed: 36228383
N Engl J Med. 2018 Dec 27;379(26):2540-2546
pubmed: 30586518
N Engl J Med. 2015 Apr 30;372(18):1734-47
pubmed: 25923553
Am J Respir Crit Care Med. 2020 Apr 15;201(8):e26-e51
pubmed: 32293205
Front Immunol. 2021 Nov 19;12:788502
pubmed: 34868074
Nat Med. 2015 Jul;21(7):665-6
pubmed: 26151325
Pediatr Rheumatol Online J. 2016 Nov 10;14(1):59
pubmed: 27832822
Sci Adv. 2023 Jul 7;9(27):eadd9984
pubmed: 37418531
Neuropathol Appl Neurobiol. 2015 Dec;41(7):952-63
pubmed: 25711697
J Immunol. 1995 Mar 15;154(6):2846-54
pubmed: 7876554

Auteurs

Hippolyte Lequain (H)

Département de Médecine Interne, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, 69004 Lyon, France.
Institut NeuroMyoGène INMG-PGNM, Physiopathologie et Génétique du Neurone et du Muscle, UMR5261, Inserm U1315, Faculté de Médecine Rockefeller, Université Claude Bernard UCBL-Lyon 1, 69008 Lyon, France.

Cyril Dégletagne (C)

CRCL Core Facilities, Centre de Recherche en Cancérologie de Lyon (CRCL) INSERM U1052-CNRS UMR5286, Université de Lyon, Université Claude Bernard Lyon1, Centre Léon Bérard, 69008 Lyon, France.

Nathalie Streichenberger (N)

Institut NeuroMyoGène INMG-PGNM, Physiopathologie et Génétique du Neurone et du Muscle, UMR5261, Inserm U1315, Faculté de Médecine Rockefeller, Université Claude Bernard UCBL-Lyon 1, 69008 Lyon, France.
Service d'Anatomopathologie, Centre de Biologie et Pathologie Est (CBPE), Hospices Civils de Lyon, 69500 Bron, France.

Julie Valantin (J)

CRCL Core Facilities, Centre de Recherche en Cancérologie de Lyon (CRCL) INSERM U1052-CNRS UMR5286, Université de Lyon, Université Claude Bernard Lyon1, Centre Léon Bérard, 69008 Lyon, France.

Thomas Simonet (T)

Institut NeuroMyoGène INMG-PGNM, Physiopathologie et Génétique du Neurone et du Muscle, UMR5261, Inserm U1315, Faculté de Médecine Rockefeller, Université Claude Bernard UCBL-Lyon 1, 69008 Lyon, France.

Laurent Schaeffer (L)

Institut NeuroMyoGène INMG-PGNM, Physiopathologie et Génétique du Neurone et du Muscle, UMR5261, Inserm U1315, Faculté de Médecine Rockefeller, Université Claude Bernard UCBL-Lyon 1, 69008 Lyon, France.
Centre de Biotechnologie Cellulaire, CHU de Lyon-HCL Groupement Est, 69677 Bron, France.

Pascal Sève (P)

Département de Médecine Interne, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, 69004 Lyon, France.
Pôle IMER, HESPER EA 7425, 69002 Lyon, France.

Pascal Leblanc (P)

Institut NeuroMyoGène INMG-PGNM, Physiopathologie et Génétique du Neurone et du Muscle, UMR5261, Inserm U1315, Faculté de Médecine Rockefeller, Université Claude Bernard UCBL-Lyon 1, 69008 Lyon, France.

Classifications MeSH